| Old Articles: <Older 7301-7310 Newer> |
|---|
 |
The Motley Fool
April 5, 2011
Frank Vinluan |
GSK in Emerging Markets: Why Sales Staff There Are Key to Global Strategy GlaxoSmithKline's rivalry with top drug companies such as Pfizer goes beyond the products they sell. In some emerging markets, it now also extends to the staff they're fighting to keep.   |
The Motley Fool
April 4, 2011
Tim Beyers |
Big, Blue ... Biotech? IBM's latest research breakthrough is a smart bomb for destroying bacteria. |
The Motley Fool
April 4, 2011
Brian Orelli |
Pfizer Tests the Breakup Waters The company announced today that it found a buyer for its Capsugel unit, which will bring in a cool $2.4 billion. |
HBS Working Knowledge
April 4, 2011
Carmen Nobel |
Attention Medical Shoppers: What Health Care Can Learn from Walmart and Amazon At a Harvard Business School discussion on health care management, experts looked to the retail industry as a possible model for delivering medical services more effectively and inexpensively. |
The Motley Fool
April 4, 2011
Brian Orelli |
Anti-Infective, Very Effective The FDA seems to like Optimer's new antibiotic. |
The Motley Fool
April 2, 2011
Luke Timmerman |
Dendreon Faces Internet-Fueled Shareholder Uprising Seattle-based Dendreon has a passionate base of fans and detractors all over the Web, but now it has a new and potentially volatile issue on its hands -- an Internet-driven shareholder uprising that aims to shake up the company's board of directors. |
The Motley Fool
April 1, 2011
Brian Orelli |
Abbott: Battle Lost, War Won A jury ordered Abbott to pay GlaxoSmithKline $3.5 million. It could have been a lot worse. |
Nursing Management
April 2011
Deborah E. Trautman |
Healthcare Reform: 1 Year Later A year after the Patient Protection and Affordable Care Act was signed into law, the nation remains divided. |
The Motley Fool
April 1, 2011
Travis Hoium |
Optimer Pharmaceuticals Shares Popped: What You Need to Know Shares of Optimer Pharmaceuticals jumped 12% today after positive news from the FDA was released. |
BusinessWeek
March 31, 2011
David Voreacos et al. |
Johnson & Johnson's Quality Catastrophe After 50-plus product recalls in 15 months, the $60 billion company is fighting to clear its once-trusted name. |
| <Older 7301-7310 Newer> Return to current articles. |
